Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

APINYA BEE VUTIKULLIRD

Allopathic & Osteopathic Physicians Family Medicine

NPI
1386816734
CMS profile
1057386
Location
CYPRESS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,050.44

52 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,566.05 21
Food and Beverage $1,484.39 31

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $2,385.12 39
CSL Behring $271.29 9
AstraZeneca Pharmaceuticals LP $239.84 2
Phathom Pharmaceuticals, Inc. $124.51 1
Takeda Pharmaceuticals U.S.A., Inc. $29.68 1

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

APINYA BEE VUTIKULLIRD

NPI 1386816734 · CMS profile ID 1057386

Allopathic & Osteopathic Physicians / Family Medicine

CYPRESS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386816734?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
APINYA BEE VUTIKULLIRD, NPI 1386816734, CMS profile ID 1057386. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386816734?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). APINYA BEE VUTIKULLIRD, NPI 1386816734, CMS profile ID 1057386. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386816734?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
APINYA BEE VUTIKULLIRD, NPI 1386816734, CMS profile ID 1057386, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1386816734?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

52 matching records · $3,050.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 52 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–52 of 52.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CSL Behring $28.6701/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604957 CMS
CSL Behring $32.8001/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604953 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $24.69 1
PY2022 $217.09 8
PY2023 $385.25 15
PY2024 $3,050.44 52
PY2025 $881.10 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $6,648,667.02 345
PY2024 Recipient $23,174.30 15
PY2024 Principal investigator $4,698,134.89 83
PY2023 Recipient $560.01 1
PY2023 Principal investigator $1,734,931.66 258
PY2022 Principal investigator $841,152.82 40
PY2021 Recipient $30,508.36 2
PY2021 Principal investigator $382,734.58 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

345 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698660
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698662
Principal investigator 1 Merck Sharp & Dohme LLC $199.06 12/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1232933454
Principal investigator 1 Boehringer Ingelheim International GmbH $8,000.00 12/26/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698251
Principal investigator 1 Boehringer Ingelheim International GmbH $2,160.00 12/22/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698253
Principal investigator 1 Eli Lilly and Company $15,571.00 12/22/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES (SYNERGY-OUTCOMES); N1T-MC-TZ01; N1T-MC-RT01 No dispute reported 06/30/2026 1187874945
Principal investigator 1 ModernaTX, Inc. $11,367.51 12/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996351
Principal investigator 1 ModernaTX, Inc. $737.10 12/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996382
Principal investigator 1 ModernaTX, Inc. $7,144.49 12/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996430
Principal investigator 1 ModernaTX, Inc. $45,944.36 12/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,707.80 12/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184278926
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 12/18/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698640
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 12/18/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698642
Principal investigator 1 Boehringer Ingelheim International GmbH $371.00 12/18/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698644
Principal investigator 1 Boehringer Ingelheim International GmbH $414.00 12/18/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698646
Principal investigator 1 Boehringer Ingelheim International GmbH $1,228.50 12/18/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698648
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 12/17/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698255
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698257
Principal investigator 1 Boehringer Ingelheim International GmbH $29.31 12/17/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698259
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187876459
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698355
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698636
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698638
Principal investigator 1 Boehringer Ingelheim International GmbH $648.00 12/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698650
Principal investigator 1 Boehringer Ingelheim International GmbH $2,988.90 11/27/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698229
Principal investigator 1 Boehringer Ingelheim International GmbH $546.75 11/27/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698235
Principal investigator 1 Boehringer Ingelheim International GmbH $15,164.55 11/27/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698241
Principal investigator 1 ModernaTX, Inc. $6,025.20 11/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996396
Principal investigator 1 ModernaTX, Inc. $2,744.67 11/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996416
Principal investigator 1 Boehringer Ingelheim International GmbH $472.50 11/21/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698223
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 11/21/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698227
Principal investigator 1 Boehringer Ingelheim International GmbH $405.00 11/21/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698231
Principal investigator 1 Boehringer Ingelheim International GmbH $405.00 11/21/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698233
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 11/21/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698237
Principal investigator 1 Boehringer Ingelheim International GmbH $405.00 11/21/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698239
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 11/21/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698245
Principal investigator 1 Boehringer Ingelheim International GmbH $6,075.00 11/21/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698247
Principal investigator 1 Eli Lilly and Company $934.02 11/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187874949
Principal investigator 1 ViiV Healthcare Company $143,985.10 11/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,454.70 11/07/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 11/07/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258897
Principal investigator 1 AstraZeneca Pharmaceuticals LP $237,249.22 11/05/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH
A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA No dispute reported 06/30/2026 1185545295
Principal investigator 1 Boehringer Ingelheim International GmbH $6,075.00 11/05/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698221
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 11/05/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698225
Principal investigator 1 Boehringer Ingelheim International GmbH $472.50 11/05/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698243
Principal investigator 1 Boehringer Ingelheim International GmbH $405.00 11/05/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698249
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698353
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698632
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698634
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698189
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698191
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698193
Principal investigator 1 Boehringer Ingelheim International GmbH $540.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698195
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698197
Principal investigator 1 Boehringer Ingelheim International GmbH $540.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698199
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698201
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698203
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698205
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698207
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698209
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698211
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698213
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698215
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698217
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698219
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698652
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698654
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/28/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698656
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/28/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698658
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 10/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698664
Principal investigator 1 Boehringer Ingelheim International GmbH $305.35 10/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698666
Principal investigator 1 Boehringer Ingelheim International GmbH $10.80 10/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698668
Principal investigator 1 Boehringer Ingelheim International GmbH $29.20 10/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698670
Principal investigator 1 ModernaTX, Inc. $2,008.40 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996341
Principal investigator 1 ModernaTX, Inc. $7,334.60 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996343
Principal investigator 1 ModernaTX, Inc. $22,872.25 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996371
Principal investigator 1 ModernaTX, Inc. $461.52 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996373
Principal investigator 1 ModernaTX, Inc. $28,577.96 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996380
Principal investigator 1 ModernaTX, Inc. $18,383.82 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996406
Principal investigator 1 ModernaTX, Inc. $2,211.30 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996412
Principal investigator 1 ModernaTX, Inc. $2,335.76 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996418
Principal investigator 1 ModernaTX, Inc. $23,430.00 10/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996420
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 10/23/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220803584
Principal investigator 1 Boehringer Ingelheim International GmbH $2,179.00 10/22/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698622
Principal investigator 1 Boehringer Ingelheim International GmbH $2,179.00 10/22/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698624
Principal investigator 1 Boehringer Ingelheim International GmbH $2,179.00 10/22/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698626
Principal investigator 1 Boehringer Ingelheim International GmbH $3,758.00 10/22/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698628
Principal investigator 1 Boehringer Ingelheim International GmbH $3,758.00 10/22/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698630
Principal investigator 1 ViiV Healthcare Company $74,071.50 10/22/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,955.11 10/16/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250517
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 10/15/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220996644
Principal investigator 1 ModernaTX, Inc. $72,009.00 10/15/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996337
Principal investigator 1 ModernaTX, Inc. $3,770.64 10/15/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996365
Principal investigator 1 ModernaTX, Inc. $4,950.00 10/15/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996404
Principal investigator 1 ModernaTX, Inc. $3,040.00 10/15/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996436
Principal investigator 1 ViiV Healthcare Company $106,744.70 10/15/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317519
Principal investigator 1 Boehringer Ingelheim International GmbH $2,250.00 10/09/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698584
Principal investigator 1 Novavax Inc $215.00 10/09/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242921572
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,055.20 10/08/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH
A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine No dispute reported 06/30/2026 1185545297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 10/03/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244549
Principal investigator 1 Boehringer Ingelheim International GmbH $1,277.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698586
Principal investigator 1 Boehringer Ingelheim International GmbH $3,179.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698588
Principal investigator 1 Boehringer Ingelheim International GmbH $2,392.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698590
Principal investigator 1 Boehringer Ingelheim International GmbH $17,103.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698592
Principal investigator 1 Boehringer Ingelheim International GmbH $945.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698594
Principal investigator 1 Boehringer Ingelheim International GmbH $1,473.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698596
Principal investigator 1 Boehringer Ingelheim International GmbH $506.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698598
Principal investigator 1 Boehringer Ingelheim International GmbH $1,473.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698600
Principal investigator 1 Boehringer Ingelheim International GmbH $17,103.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698602
Principal investigator 1 Boehringer Ingelheim International GmbH $1,277.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698604
Principal investigator 1 Boehringer Ingelheim International GmbH $3,179.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698606
Principal investigator 1 Boehringer Ingelheim International GmbH $2,392.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698608
Principal investigator 1 Boehringer Ingelheim International GmbH $17,103.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698610
Principal investigator 1 Boehringer Ingelheim International GmbH $3,758.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698612
Principal investigator 1 Boehringer Ingelheim International GmbH $3,179.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698614
Principal investigator 1 Boehringer Ingelheim International GmbH $2,392.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698616
Principal investigator 1 Boehringer Ingelheim International GmbH $17,103.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698618
Principal investigator 1 Boehringer Ingelheim International GmbH $1,277.00 10/02/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698620
Principal investigator 1 ViiV Healthcare Company $115,965.90 10/02/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317511
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698351
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698580
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698582
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/30/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698576
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/30/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698578
Principal investigator 1 ViiV Healthcare Company $14,936.25 09/25/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317471
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 09/24/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698181
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 09/24/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698183
Principal investigator 1 Boehringer Ingelheim International GmbH $693.50 09/24/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698185
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 09/24/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698187
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 09/24/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698271
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 09/24/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698273
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 09/24/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698275
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 09/24/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698277
Principal investigator 1 ViiV Healthcare Company $73,268.00 09/24/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 09/18/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184240834
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 09/12/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220803582
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,000.00 09/11/2025 Non-covered Recipient Entity
Interspond LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220795469
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,900.00 09/11/2025 Non-covered Recipient Entity
Interspond LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220795471
Principal investigator 1 ModernaTX, Inc. $6,375.00 09/11/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996414
Principal investigator 1 ViiV Healthcare Company $46,300.00 09/10/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317469
Principal investigator 1 Novavax Inc $2,250.00 09/04/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242918711
Principal investigator 1 ViiV Healthcare Company $2,700.00 09/04/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317509
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698345
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698556
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698558
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 08/29/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698572
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/29/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698574
Principal investigator 1 Novavax Inc $8,000.00 08/27/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242921209
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698347
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698349
Principal investigator 1 ViiV Healthcare Company $93,670.00 08/25/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317477
Principal investigator 1 ViiV Healthcare Company $522.21 08/22/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317463
Principal investigator 1 ViiV Healthcare Company $237,761.24 08/15/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317465
Principal investigator 1 Novavax Inc $967.50 08/06/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242920344
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698337
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698339
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698341
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220698343
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698548
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698550
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698552
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698554
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 07/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698568
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698570
Principal investigator 1 ModernaTX, Inc. $40,168.00 07/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996333
Principal investigator 1 ModernaTX, Inc. $11,483.78 07/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996335
Principal investigator 1 ModernaTX, Inc. $1,631.70 07/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996355
Principal investigator 1 ModernaTX, Inc. $310.63 07/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996367
Principal investigator 1 ModernaTX, Inc. $4,881.25 07/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996369
Principal investigator 1 ModernaTX, Inc. $115.38 07/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996378
Principal investigator 1 ModernaTX, Inc. $737.10 07/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996384
Principal investigator 1 ModernaTX, Inc. $2,744.67 07/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996394
Principal investigator 1 Boehringer Ingelheim International GmbH $2,257.00 07/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698530
Principal investigator 1 Boehringer Ingelheim International GmbH $2,257.00 07/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698532
Principal investigator 1 Boehringer Ingelheim International GmbH $2,257.00 07/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698534
Principal investigator 1 Boehringer Ingelheim International GmbH $1,135.00 07/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698538
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 07/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698542
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 07/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698546
Principal investigator 1 ViiV Healthcare Company $698,270.11 07/23/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 07/17/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217030
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.00 07/07/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698524
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.00 07/07/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698526
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.00 07/07/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698528
Principal investigator 1 Boehringer Ingelheim International GmbH $1,135.00 07/07/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698536
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 07/07/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698540
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 07/07/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698544
Principal investigator 1 ViiV Healthcare Company $71,424.00 07/07/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 07/04/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184212787
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698560
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698562
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698564
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698566
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/30/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698512
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 06/30/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698514
Principal investigator 1 ModernaTX, Inc. $3,685.50 06/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996359
Principal investigator 1 ModernaTX, Inc. $84,933.75 06/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996388
Principal investigator 1 ModernaTX, Inc. $50,011.43 06/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996390
Principal investigator 1 ModernaTX, Inc. $15,900.01 06/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996424
Principal investigator 1 ViiV Healthcare Company $857,318.17 06/20/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317667
Principal investigator 1 Novavax Inc $475.00 06/19/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242920794
Principal investigator 1 Novavax Inc $2,365.00 06/13/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242920798
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,500.00 06/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PROFESSIONALS, LLC
A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine No dispute reported 06/30/2026 1185545293
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698494
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698496
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698498
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698500
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/30/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698508
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 05/30/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698510
Principal investigator 1 ModernaTX, Inc. $4,574.45 05/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996339
Principal investigator 1 Novavax Inc $350.00 05/28/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242921205
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 05/27/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698267
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698269
Principal investigator 1 Boehringer Ingelheim International GmbH $1,075.00 05/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698474
Principal investigator 1 Boehringer Ingelheim International GmbH $1,075.00 05/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698476
Principal investigator 1 Boehringer Ingelheim International GmbH $757.00 05/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698478
Principal investigator 1 Boehringer Ingelheim International GmbH $393.00 05/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698480
Principal investigator 1 Boehringer Ingelheim International GmbH $16,833.00 05/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698482
Principal investigator 1 Boehringer Ingelheim International GmbH $1,075.00 05/27/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698484
Principal investigator 1 AstraZeneca Pharmaceuticals LP $278,141.36 05/23/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185545299
Principal investigator 1 Novavax Inc $2,795.00 05/15/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242920339
Principal investigator 1 ViiV Healthcare Company $14,800.00 05/09/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317467
Principal investigator 1 ViiV Healthcare Company $1,200.00 05/09/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317475
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698486
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698488
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698490
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698492
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 04/30/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698502
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 04/30/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698504
Principal investigator 1 ModernaTX, Inc. $8,234.01 04/30/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996398
Principal investigator 1 ModernaTX, Inc. $21,579.50 04/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996347
Principal investigator 1 ModernaTX, Inc. $19,610.15 04/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996361
Principal investigator 1 ModernaTX, Inc. $3,685.50 04/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996386
Principal investigator 1 ModernaTX, Inc. $11,657.59 04/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996410
Principal investigator 1 ModernaTX, Inc. $3,989.70 04/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996422
Principal investigator 1 ModernaTX, Inc. $14,145.30 04/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996426
Principal investigator 1 ModernaTX, Inc. $91,014.59 04/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996432
Principal investigator 1 ModernaTX, Inc. $50,132.16 04/28/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996434
Principal investigator 1 Boehringer Ingelheim International GmbH $16,023.00 04/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698454
Principal investigator 1 Boehringer Ingelheim International GmbH $16,023.00 04/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698456
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 04/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698458
Principal investigator 1 Boehringer Ingelheim International GmbH $1,135.00 04/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698460
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 04/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698462
Principal investigator 1 Boehringer Ingelheim International GmbH $16,023.00 04/25/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698464
Principal investigator 1 ViiV Healthcare Company $102,800.00 04/25/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
PHASE 1, OPEN-LABEL, RANDOMISED CROSSOVER STUDY ASSESSING THE TOLERABI No dispute reported 06/30/2026 1190317521
Principal investigator 1 Amgen Inc. $48,778.00 04/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1246642858
Principal investigator 1 Novavax Inc $475.00 04/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919908
Principal investigator 1 Novavax Inc $2,150.00 04/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242921201
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 04/23/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698261
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 04/23/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698263
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 04/23/2025 Non-covered Recipient Entity
Ark Clinical Research
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220698265
Principal investigator 1 Boehringer Ingelheim International GmbH $1,314.00 04/23/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698516
Principal investigator 1 Boehringer Ingelheim International GmbH $366.42 04/23/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698518
Principal investigator 1 Boehringer Ingelheim International GmbH $13.50 04/23/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698520
Principal investigator 1 Boehringer Ingelheim International GmbH $82.49 04/23/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698522
Principal investigator 1 ModernaTX, Inc. $36.50 04/23/2025 Non-covered Recipient Entity
ARK Clinical Research, LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996392
Principal investigator 1 Boehringer Ingelheim International GmbH $15.84 04/20/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698506
Principal investigator 1 Boehringer Ingelheim International GmbH $3,730.00 04/11/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698466
Principal investigator 1 Boehringer Ingelheim International GmbH $3,730.00 04/11/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698468
Principal investigator 1 Boehringer Ingelheim International GmbH $1,135.00 04/11/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698470
Principal investigator 1 Boehringer Ingelheim International GmbH $3,730.00 04/11/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698472
Principal investigator 1 ModernaTX, Inc. $49.89 04/03/2025 Non-covered Recipient Entity
ARK Clinical Research, LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996375
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698446
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698448
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698450
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698452
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 03/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698429
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 03/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698431
Principal investigator 1 Novavax Inc $4,432.43 03/27/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919056
Principal investigator 1 Novavax Inc $350.00 03/27/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919412
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.00 03/03/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698433
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 03/03/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698435
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 03/03/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698438
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 03/03/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698440
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 03/03/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698442
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 03/03/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698444
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698411
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698413
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698415
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698417
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/28/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698425
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 02/28/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698427
Principal investigator 1 ModernaTX, Inc. $14,648.48 02/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996400
Principal investigator 1 Novavax Inc $4,757.54 02/27/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919916
Principal investigator 1 ModernaTX, Inc. $2,000.00 02/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252966375
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/19/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252966377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,955.11 02/18/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,071.00 02/18/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184154182
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698403
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698405
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698407
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698409
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 01/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698419
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 01/31/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698421
Principal investigator 1 Amgen Inc. $32,041.78 01/30/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH- TUSTIN
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1246639355
Principal investigator 1 AstraZeneca Pharmaceuticals LP $314,768.25 01/29/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185545287
Principal investigator 1 AstraZeneca Pharmaceuticals LP $65,865.00 01/29/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH
A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C No dispute reported 06/30/2026 1185545291
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 01/27/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698175
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 01/27/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698177
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 01/27/2025 Non-covered Recipient Entity
Ark Clinical Research
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220698179
Principal investigator 1 Eli Lilly and Company $7,465.64 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187876899
Principal investigator 1 ModernaTX, Inc. $1,829.78 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252996345
Principal investigator 1 ModernaTX, Inc. $28,922.40 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996349
Principal investigator 1 ModernaTX, Inc. $28,014.50 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996357
Principal investigator 1 ModernaTX, Inc. $3,554.46 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996363
Principal investigator 1 ModernaTX, Inc. $1,250.97 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996402
Principal investigator 1 ModernaTX, Inc. $12,947.70 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996408
Principal investigator 1 ModernaTX, Inc. $13,667.72 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996428
Principal investigator 1 ModernaTX, Inc. $4,243.59 01/27/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996438
Principal investigator 1 Novavax Inc $4,355.08 01/23/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919911
Principal investigator 1 Eli Lilly and Company $24.90 01/22/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187875969
Principal investigator 1 Eli Lilly and Company $90,912.00 01/21/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187877177
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,034.00 01/15/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185545301
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698357
Principal investigator 1 Boehringer Ingelheim International GmbH $3,402.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698359
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698361
Principal investigator 1 Boehringer Ingelheim International GmbH $2,796.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698363
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698365
Principal investigator 1 Boehringer Ingelheim International GmbH $3,402.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698367
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698369
Principal investigator 1 Boehringer Ingelheim International GmbH $2,796.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698371
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698373
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698375
Principal investigator 1 Boehringer Ingelheim International GmbH $3,402.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698377
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698379
Principal investigator 1 Boehringer Ingelheim International GmbH $2,796.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698381
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698383
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698385
Principal investigator 1 Boehringer Ingelheim International GmbH $3,402.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698387
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698389
Principal investigator 1 Boehringer Ingelheim International GmbH $2,796.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698391
Principal investigator 1 Boehringer Ingelheim International GmbH $3,044.00 01/15/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698393
Principal investigator 1 AstraZeneca UK Limited $134,099.80 01/13/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185545289
Principal investigator 1 ModernaTX, Inc. $75.13 01/13/2025 Non-covered Recipient Entity
Ark Clinical Research
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252996353
Principal investigator 1 Boehringer Ingelheim International GmbH $79.18 01/08/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698423
Principal investigator 1 Eli Lilly and Company $3,240.60 01/08/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187873805
Principal investigator 1 Eli Lilly and Company $1,399.18 01/08/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187874647
Principal investigator 1 Eli Lilly and Company $146,367.00 01/07/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187874167
Principal investigator 1 Eli Lilly and Company $134,551.00 01/07/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187874645
Principal investigator 1 Eli Lilly and Company $507,884.00 01/07/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187874941
Principal investigator 1 Eli Lilly and Company $648,593.89 01/07/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187876457
Principal investigator 1 Eli Lilly and Company $2,773.96 01/07/2025 Non-covered Recipient Entity
ARK CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187877175
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698395
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698397
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698399
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Ark Clinical Research
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220698401